These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

331 related articles for article (PubMed ID: 19000361)

  • 21. Comparison of cardiovascular outcomes in elderly patients with diabetes who initiated rosiglitazone vs pioglitazone therapy.
    Winkelmayer WC; Setoguchi S; Levin R; Solomon DH
    Arch Intern Med; 2008 Nov; 168(21):2368-75. PubMed ID: 19029503
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cardiovascular risk and cardiometabolic protection: role of glitazones.
    Petrazzi L; Grassi D; Polidoro L; D'Aurelio A; Croce G; Properzi G; Tiberti S; Desideri G; Ferri C
    J Nephrol; 2008; 21(6):826-35. PubMed ID: 19034866
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Thiazolidinediones and the influence of media adverse reporting on prescribing attitudes in practice (TZD-IMPACT) study.
    George J; Hannah S; Lang CC
    Cardiovasc Ther; 2009; 27(2):83-8. PubMed ID: 19426244
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The risk of developing coronary artery disease or congestive heart failure, and overall mortality, in type 2 diabetic patients receiving rosiglitazone, pioglitazone, metformin, or sulfonylureas: a retrospective analysis.
    Pantalone KM; Kattan MW; Yu C; Wells BJ; Arrigain S; Jain A; Atreja A; Zimmerman RS
    Acta Diabetol; 2009 Jun; 46(2):145-54. PubMed ID: 19194648
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Diabetes prevention: still no effective drugs.
    Prescrire Int; 2007 Dec; 16(92):258. PubMed ID: 18095391
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cardiovascular risk and thiazolidinediones--what do meta-analyses really tell us?
    Schernthaner G; Chilton RJ
    Diabetes Obes Metab; 2010 Dec; 12(12):1023-35. PubMed ID: 20977573
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Thiazolidinediones and heart failure: a teleo-analysis.
    Singh S; Loke YK; Furberg CD
    Diabetes Care; 2007 Aug; 30(8):2148-53. PubMed ID: 17536074
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The controversial effects of thiazolidinediones on cardiovascular morbidity and mortality.
    Stafylas PC; Sarafidis PA; Lasaridis AN
    Int J Cardiol; 2009 Jan; 131(3):298-304. PubMed ID: 18684530
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Thiazolidinediones and congestive heart failure: a judicious balance of risks and benefits.
    Patel RR
    Cardiol Rev; 2009; 17(3):132-5. PubMed ID: 19384087
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Rosiglitazone, myocardial ischemic risk, and recent regulatory actions.
    Bourg CA; Phillips BB
    Ann Pharmacother; 2012 Feb; 46(2):282-9. PubMed ID: 22298606
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Rosiglitazone: what went wrong?
    Cohen D
    BMJ; 2010 Sep; 341():c4848. PubMed ID: 20819889
    [No Abstract]   [Full Text] [Related]  

  • 32. [Rosiglitazone].
    Taéron C
    Rev Infirm; 2006 Feb; (118):33-4. PubMed ID: 16562551
    [No Abstract]   [Full Text] [Related]  

  • 33. Antidiabetic prescribing trends and predictors of thiazolidinedione discontinuation following the 2007 rosiglitazone safety alert.
    Hurren KM; Taylor TN; Jaber LA
    Diabetes Res Clin Pract; 2011 Jul; 93(1):49-55. PubMed ID: 21440324
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Thiazolidinedione insulin sensitizers and the heart: a tale of two organs?
    Buckingham RE; Hanna A
    Diabetes Obes Metab; 2008 Apr; 10(4):312-28. PubMed ID: 18333890
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Balancing risk and benefit with oral hypoglycemic drugs.
    Hamnvik OP; McMahon GT
    Mt Sinai J Med; 2009 Jun; 76(3):234-43. PubMed ID: 19421967
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Thiazolidinediones and cardiovascular risk: will the evidence so far available modify treatment strategies for type 2 diabetes?
    Vaccaro O; Riccardi G
    Nutr Metab Cardiovasc Dis; 2008 Feb; 18(2):85-7. PubMed ID: 18280715
    [No Abstract]   [Full Text] [Related]  

  • 37. A comparison of pioglitazone and rosiglitazone for hospitalization for acute myocardial infarction in type 2 diabetes.
    Gerrits CM; Bhattacharya M; Manthena S; Baran R; Perez A; Kupfer S
    Pharmacoepidemiol Drug Saf; 2007 Oct; 16(10):1065-71. PubMed ID: 17674425
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Risk of acute myocardial infarction in patients treated with thiazolidinediones or other antidiabetic medications.
    Stockl KM; Le L; Zhang S; Harada AS
    Pharmacoepidemiol Drug Saf; 2009 Feb; 18(2):166-74. PubMed ID: 19109802
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Rosiglitazone-associated fractures in type 2 diabetes: an Analysis from A Diabetes Outcome Progression Trial (ADOPT).
    Kahn SE; Zinman B; Lachin JM; Haffner SM; Herman WH; Holman RR; Kravitz BG; Yu D; Heise MA; Aftring RP; Viberti G;
    Diabetes Care; 2008 May; 31(5):845-51. PubMed ID: 18223031
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Management of atypical antipsychotic drug-induced weight gain: focus on metformin.
    Miller LJ
    Pharmacotherapy; 2009 Jun; 29(6):725-35. PubMed ID: 19476423
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.